Israel’s Taro Cancels Acquisition Pact With India’s Sun Pharma
This article was originally published in PharmAsia News
Executive Summary
Israel's Taro Pharmaceuticals has canceled its year-old agreement with India's Sun Pharmaceutical Industries to agree to a Sun subsidiary's takeover of the firm. Sun and Taro agreed last year to a $455 million acquisition by Aditya Acquisition, a Sun subsidiary, but Taro directors have voted unanimously to cancel the agreement after Taro managed to turn around its fortunes in the ensuing months. Sun, which owns just over a third of Taro, had offered to raise the original share offer, but Taro directors turned it down and exercised an agreement provision that allowed the Israeli drug maker to cancel the merger
You may also be interested in...
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.